Celcuity Inc (CELC)

$50.51 +1.09 (2.21%)
Market Cap 2.10B
Revenue (ttm) 0.00
Net Income (ttm) -111.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 2.24
Volume 1,476,100
Avg Vol 1,775,106
Day's Range N/A - N/A
Shares Out 42.43M
Stochastic %K 59%
Beta 0.70
Analysts Strong Sell
Price Target $74.50

Company Profile

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 neg...

Industry: Biotechnology
Sector: Healthcare
Phone: (763) 392-0767
Address:
16305 36th Avenue North, Suite 100, Minneapolis, United States
JarvisFlow
JarvisFlow Oct. 3 at 10:38 AM
Needham has adjusted their stance on Celcuity ( $CELC ), setting the rating to Buy with a target price of 70.
0 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 8:55 PM
$CELC: Unusual Options Activity Alerted CALL flow observed 500x contracts at Strike price of $50 Exp on 11/21/2025 with Premium of $275K and showing NEUTRAL Sentiment
0 · Reply
B71
B71 Oct. 2 at 7:57 PM
$CELC if they get fda approval they will for sure get acquired by a big name.
1 · Reply
HappyStockholder
HappyStockholder Oct. 2 at 7:06 PM
$CELC Appears to be a nice bounce back day so far. Heading in the right direction again.
0 · Reply
HappyStockholder
HappyStockholder Oct. 2 at 4:04 PM
$CELC Schwab has reinstituted its “high risk” restriction on CELC. Purchases are currently not allowed on line. They can only be made by calling one of their brokers and asking them to place the trade. There is no extra charge for this.
0 · Reply
MakeM0ney_444
MakeM0ney_444 Oct. 1 at 7:24 PM
$CELC so why the big sell off?
2 · Reply
francolep
francolep Oct. 1 at 5:30 PM
$CELC this company is extremely derisked, unprecedented Ph3 results, super fast track approved by FDA, 5B peak revenues, should be worth at least 15-20 B with a standard 3-4x multiple. Lots of insider buys, all analysts have huge upsides. Essentially it’s a no-brainer, a free lunch as Mohnish Pabrai would say
1 · Reply
PacBoiLar
PacBoiLar Oct. 1 at 4:28 PM
$CELC just a reminder that ESMO readout is October 18, baker bros bought at 59, and Brian or Lance haven’t sold a share since the pop back in july. The story here is just getting started. My two cents is that retail is getting impatient and short sellers are taking advantage of low volume
2 · Reply
MakeM0ney_444
MakeM0ney_444 Oct. 1 at 3:47 PM
$CELC damn what’s goin on today?
0 · Reply
PacBoiLar
PacBoiLar Sep. 30 at 2:14 PM
$CELC extremely low volume, adding here. Patience will pay
0 · Reply
Latest News on CELC
Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress

Sep 22, 2025, 9:15 AM EDT - 12 days ago

Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress

Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance

Sep 9, 2025, 4:01 PM EDT - 25 days ago

Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance

Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA's Real-Time Oncology Review Program

Aug 27, 2025, 4:05 PM EDT - 5 weeks ago

Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA's Real-Time Oncology Review Program

Celcuity Inc. (CELC) Q2 2025 Earnings Call Transcript

Aug 15, 2025, 11:40 AM EDT - 7 weeks ago

Celcuity Inc. (CELC) Q2 2025 Earnings Call Transcript

Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 4:01 PM EDT - 7 weeks ago

Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call

Aug 7, 2025, 7:05 AM EDT - 2 months ago

Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call

Celcuity: Positive Phase 3 Wild-Type ABC Data With Gedatolisib Leads To End Of 2025 Catalyst

Jul 30, 2025, 3:42 PM EDT - 2 months ago

Celcuity: Positive Phase 3 Wild-Type ABC Data With Gedatolisib Leads To End Of 2025 Catalyst

Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants

Jul 30, 2025, 6:30 AM EDT - 2 months ago

Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants

Celcuity: What's Happening With CELC Stock?

Jul 29, 2025, 6:40 AM EDT - 2 months ago

Celcuity: What's Happening With CELC Stock?

Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock

Jul 28, 2025, 4:02 PM EDT - 2 months ago

Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock

Celcuity shares skyrocket as breast cancer drug combo shows dramatic Phase 3 success

Jul 28, 2025, 3:02 PM EDT - 2 months ago

Celcuity shares skyrocket as breast cancer drug combo shows dramatic Phase 3 success

Celcuity's triple cancer drug combo tops AstraZeneca's in cutting progression in study

Jul 28, 2025, 7:49 AM EDT - 2 months ago

Celcuity's triple cancer drug combo tops AstraZeneca's in cutting progression in study

Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial

Jul 28, 2025, 7:00 AM EDT - 2 months ago

Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial

Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer

Jul 25, 2025, 4:05 PM EDT - 2 months ago

Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer

Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer

Jul 24, 2025, 4:01 PM EDT - 2 months ago

Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer

Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042

Jul 14, 2025, 7:05 AM EDT - 2 months ago

Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042

Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib

Jun 30, 2025, 7:05 AM EDT - 3 months ago

Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib

Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences

May 21, 2025, 7:05 AM EDT - 4 months ago

Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences

Celcuity Inc. (CELC) Q1 2025 Earnings Call Transcript

May 14, 2025, 9:36 PM EDT - 5 months ago

Celcuity Inc. (CELC) Q1 2025 Earnings Call Transcript

Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:01 PM EDT - 5 months ago

Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call

May 7, 2025, 7:05 AM EDT - 5 months ago

Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

Apr 1, 2025, 7:05 AM EDT - 6 months ago

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

Celcuity Inc. (CELC) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 10:50 PM EDT - 6 months ago

Celcuity Inc. (CELC) Q4 2024 Earnings Call Transcript

Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 31, 2025, 4:01 PM EDT - 6 months ago

Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call

Mar 24, 2025, 7:05 AM EDT - 6 months ago

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call

Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences

Feb 25, 2025, 7:05 AM EST - 7 months ago

Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences

Celcuity's High-Stakes Oncology Bet Is Underappreciated

Feb 19, 2025, 6:24 PM EST - 8 months ago

Celcuity's High-Stakes Oncology Bet Is Underappreciated

Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium

Dec 11, 2024, 7:05 AM EST - 10 months ago

Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium

Celcuity Inc. (CELC) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 7:42 PM EST - 11 months ago

Celcuity Inc. (CELC) Q3 2024 Earnings Call Transcript

Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update

Nov 14, 2024, 4:01 PM EST - 11 months ago

Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update

Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences

Nov 12, 2024, 7:05 AM EST - 11 months ago

Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences

Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call

Nov 7, 2024, 7:05 AM EST - 11 months ago

Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call

Celcuity Inc. (CELC) Q2 2024 Earnings Call Transcript

Aug 16, 2024, 3:50 PM EDT - 1 year ago

Celcuity Inc. (CELC) Q2 2024 Earnings Call Transcript

Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update

Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call

Aug 7, 2024, 7:05 AM EDT - 1 year ago

Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call

Celcuity: Flying A Phase 3 Trial Right Under Your Nose

Jul 5, 2024, 12:05 AM EDT - 1 year ago

Celcuity: Flying A Phase 3 Trial Right Under Your Nose

Celcuity To Participate in Jefferies Global Healthcare Conference

Jun 3, 2024, 4:01 PM EDT - 1 year ago

Celcuity To Participate in Jefferies Global Healthcare Conference

Celcuity Announces Pricing of Underwritten Common Stock Offering

May 30, 2024, 7:36 AM EDT - 1 year ago

Celcuity Announces Pricing of Underwritten Common Stock Offering

Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing

May 30, 2024, 7:00 AM EDT - 1 year ago

Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing

Celcuity Inc. (CELC) Q1 2024 Earnings Call Transcript

May 15, 2024, 7:43 PM EDT - 1 year ago

Celcuity Inc. (CELC) Q1 2024 Earnings Call Transcript

Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update

May 15, 2024, 4:01 PM EDT - 1 year ago

Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update

Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call

May 8, 2024, 7:05 AM EDT - 1 year ago

Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call

Celcuity Inc. (CELC) Q4 2023 Earnings Call Transcript

Mar 27, 2024, 6:40 PM EDT - 1 year ago

Celcuity Inc. (CELC) Q4 2023 Earnings Call Transcript

Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 27, 2024, 4:01 PM EDT - 1 year ago

Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call

Mar 20, 2024, 7:05 AM EDT - 1 year ago

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call

Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024

Mar 6, 2024, 7:05 AM EST - 1 year ago

Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024

Celcuity to Participate in Cowen's 44th Annual Health Care Conference

Feb 28, 2024, 7:05 AM EST - 1 year ago

Celcuity to Participate in Cowen's 44th Annual Health Care Conference

Celcuity Appoints Eldon Mayer as Chief Commercial Officer

Feb 20, 2024, 7:05 AM EST - 1 year ago

Celcuity Appoints Eldon Mayer as Chief Commercial Officer

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium

Dec 6, 2023, 8:30 AM EST - 1 year ago

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium

Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium

Dec 1, 2023, 11:02 AM EST - 2 years ago

Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium

JarvisFlow
JarvisFlow Oct. 3 at 10:38 AM
Needham has adjusted their stance on Celcuity ( $CELC ), setting the rating to Buy with a target price of 70.
0 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 8:55 PM
$CELC: Unusual Options Activity Alerted CALL flow observed 500x contracts at Strike price of $50 Exp on 11/21/2025 with Premium of $275K and showing NEUTRAL Sentiment
0 · Reply
B71
B71 Oct. 2 at 7:57 PM
$CELC if they get fda approval they will for sure get acquired by a big name.
1 · Reply
HappyStockholder
HappyStockholder Oct. 2 at 7:06 PM
$CELC Appears to be a nice bounce back day so far. Heading in the right direction again.
0 · Reply
HappyStockholder
HappyStockholder Oct. 2 at 4:04 PM
$CELC Schwab has reinstituted its “high risk” restriction on CELC. Purchases are currently not allowed on line. They can only be made by calling one of their brokers and asking them to place the trade. There is no extra charge for this.
0 · Reply
MakeM0ney_444
MakeM0ney_444 Oct. 1 at 7:24 PM
$CELC so why the big sell off?
2 · Reply
francolep
francolep Oct. 1 at 5:30 PM
$CELC this company is extremely derisked, unprecedented Ph3 results, super fast track approved by FDA, 5B peak revenues, should be worth at least 15-20 B with a standard 3-4x multiple. Lots of insider buys, all analysts have huge upsides. Essentially it’s a no-brainer, a free lunch as Mohnish Pabrai would say
1 · Reply
PacBoiLar
PacBoiLar Oct. 1 at 4:28 PM
$CELC just a reminder that ESMO readout is October 18, baker bros bought at 59, and Brian or Lance haven’t sold a share since the pop back in july. The story here is just getting started. My two cents is that retail is getting impatient and short sellers are taking advantage of low volume
2 · Reply
MakeM0ney_444
MakeM0ney_444 Oct. 1 at 3:47 PM
$CELC damn what’s goin on today?
0 · Reply
PacBoiLar
PacBoiLar Sep. 30 at 2:14 PM
$CELC extremely low volume, adding here. Patience will pay
0 · Reply
highnihilism
highnihilism Sep. 30 at 9:13 AM
$LDOS Leidos: 149 trades, $166K vs $315K avg (0.53x). $89K calls / $76K puts. $ORC Orchid Island Capital: 70 trades, $92K vs $14K avg (6.76x !!!). $89K calls / $4K puts. $CELC Celcuity: 27 trades, $90K vs $260K avg (0.35x). $88K calls / $2K puts. $URBN Urban Outfitters: 306 trades, $213K vs $1.11M avg (0.19x). $88K calls / $124K puts.
0 · Reply
widgeon7
widgeon7 Sep. 29 at 7:56 PM
$CELC Expect the first of the rolling submissions for the New Drug Application (NDA) of gedatolisib soon
0 · Reply
SweepCastApp
SweepCastApp Sep. 28 at 11:23 PM
$CELC: Unusual Options Activity Alerted CALL flow observed 149x contracts at Strike price of $55 Exp on 12/19/2025 with Premium of $86K and showing BEARISH Sentiment
1 · Reply
samjoyst
samjoyst Sep. 26 at 11:27 PM
$CELC reminder that Baker Bros filed 10% ownership at ~$56 and $58 just two weeks ago. Excited to see what the ESMO presentation will bring!
0 · Reply
Denko87
Denko87 Sep. 26 at 6:39 PM
$CELC It doesn't look good. The volume is drastically decreasing. It's been falling for 3 days in a row.
1 · Reply
kshonstocks
kshonstocks Sep. 25 at 5:19 PM
$CELC another weak day on wimpy volume
1 · Reply
HappyStockholder
HappyStockholder Sep. 24 at 1:28 PM
$CELC Schwab has lifted trading restrictions on CELC. You no longer need to call them to place a trade. It has been removed from their “risky stock” list.
0 · Reply
B71
B71 Sep. 23 at 9:06 PM
$CELC is this name going to come back to life?
0 · Reply
kshonstocks
kshonstocks Sep. 22 at 5:39 PM
$CELC trying to turn
0 · Reply
JasonCO
JasonCO Sep. 22 at 5:19 PM
$CELC $30’s?
1 · Reply
HappyStockholder
HappyStockholder Sep. 22 at 1:27 PM
$CELC CELC announces this morning that pivotal phase 3 Victoria-1 Trial will be revealed at ESMO Congress, Oct. 17-21. Maybe Guggenheim knows something?
0 · Reply
kshonstocks
kshonstocks Sep. 22 at 1:07 PM
Reminder--lots of shorts in the $CELC https://shortsqueeze.com/?symbol=celc
0 · Reply